Could a new isotretinoin drug be the answer to quelling the drug's saftey concerns?
According to Dr. Hilary E. Baldwin, vice chair of the Department of Dermatology at SUNY-Downstate in Brooklyn, N.Y., the answer could be yes, and a new isotretinoin drug may be just around the corner.
She reported the news at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).
She said that a phase III trial of CIP-isotretinoin (Cipher Pharmaceuticals) is wrapping up and results will soon be submitted to the FDA for review.
According to Dr. Baldwin, the drug addresses safety concerns, such as IBD and depression. The gelatin capsules of CIP-istoretinoin help reduce GI irratation and the drug is less food dependent.
But it won't solve all isotretinoin's problems.
Phase III CIP-isotretinoin results should be released in the near future. We'll keep you posted!
- Amy Pfeiffer
SDEF and this news organization are owned by Elsevier.